Organisation paid for research Program year 2024 Source: CMS Open Payments

Bluegrass Community Research Inc

Neither a doctor nor a teaching hospital

Research payments

$1,497,590

284 payments

Through program year 2024, Bluegrass Community Research Inc is reported as receiving $1,497,590 in research payments, across 284 payments.

By program year

6 rows
Year Kind Amount Payments
2024 Research $44,236 6
2023 Research $52,340 6
2022 Research $133,320 37
2021 Research $377,710 88
2020 Research $515,976 78
2019 Research $374,007 69

Breakdown

Who paid Research payments · program years 2019–2024
  1. Gilead Sciences, Inc. $473,006 54 payments
  2. AbbVie, Inc. $374,572 80 payments
  3. Eli Lilly and Company $269,885 31 payments
  4. Sun Pharmaceutical Industries Inc. $147,726 75 payments
  5. Ucb SA $86,644 7 payments
  6. Horizon Therapeutics plc $57,324 3 payments
  7. Pfizer Inc. $45,325 19 payments
  8. Regeneron Pharmaceuticals, Inc. $28,141 10 payments
  9. Kiniksa Pharmaceuticals International, plc $8,194 3 payments
  10. Amgen Inc. $6,110 1 payment
Studies the money was for Research payments · program years 2019–2024
  1. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus $181,963 8 payments
  2. M15-925 $132,434 22 payments
  3. M13-549 $109,995 24 payments
  4. A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (Sle) $86,771 7 payments
  5. A Long Term Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis. $48,588 12 payments
  6. A Multicenter, Open-Label, Follow-Up Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis $46,220 4 payments
  7. A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis $40,424 3 payments
  8. A Multiple-Dose, Long-Term Extension Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis Who Have Previously Completed Studies With Tildrakizumab $37,629 15 payments
  9. A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing Upadacitinib (ABT-494) to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs) $36,732 10 payments
  10. Phase III Pivotal Study 1 of Tofacitinib Cp690550 in Ankylosing Spondylitis $36,253 17 payments
What the money was spent on Research payments · program years 2019–2024
  1. Other $97,228 28 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record